US equities |
NVDA $236.05 ▲+2.25% MU $1,080.52 ▼-1.54% TSLA $371.20 ▲+4.83% SPCX $157.25 ▲+6.20% SNDK $1,726.71 ▼-3.41% AMD $631.36 ▲+2.54% STX $827.61 ▼-12.48% WDC $404.38 ▼-12.58%
FinancialContent

Articles published by MannKind

< Previous 1 2 3 Next >
News headline image
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind to Present at Upcoming Conferences
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Repays Certain Debt Obligations
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Announces CFO Transition
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation Announces Participation at Upcoming Conferences
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation Reports 2023 Third Quarter Financial Results
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation Announces Participation at Upcoming Conferences
From MannKind
Via GlobeNewswire
Tickers MNKD
< Previous 1 2 3 Next >